Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis

Solid Q4 beat overshadowed by prudent guidance that removes 4 "imminent" replacement system sales from FY2022 outlook. As per quarterly call, all have physician/administration support and remain “imminent”.

Stereotaxis: Replacement Cycle Timeline Drives Prudent Guidance, Creates Compelling Opportunity

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q4 2021 Results - Earnings Call Transcript

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Stereotaxis Reports 2021 Full Year Financial Results

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

"Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member. Innovation Day showcased significant catalysts ahead including multiple regulatory milestones & commercial product launches; company well positioned to become the Intuitive Surgical of endovascular surgery.

Stereotaxis: Driving Robotic Revolution In Endovascular Surgery; Acquisition Potential Rising

ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with installation of Stereotaxis' Robotic Magnetic Navigation technology. Chief physicians for arrhythmia treatment, Dr. Chen Ke and Dr. Song Weifeng, successfully performed their first robotic cardiac ablation procedure, treating a patient who suffered from a complex ventricular arrhythmia.

Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China

ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona. HonorHealth is among the first in the nation to offer the Genesis Robotic Magnetic Navigation (RMN) system to patients receiving minimally invasive cardiac ablation procedures.

HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders

ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism.”

Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the company's innovation pipeline by members of Stereotaxis leadership with a live Q&A session.

Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics

ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.

BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment

The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) increased by 20.5% today. This is why it happened.

Stereotaxis (STXS) Stock: Why The Price Surged Today

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2021 Results - Earnings Call Transcript

ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021.

Stereotaxis Reports 2021 Third Quarter Financial Results

ST. LOUIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) on November 12-13.

Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting

Stereotaxis Inc. (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Stereotaxis Inc. (STXS) Q3 Earnings Expected to Decline

ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021

ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.

First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology

The stock price of Stereotaxis Inc (NYSEAMERICAN: STXS) has seen an uptick this week. This is why it happened.

STXS Stock: Why It Increased This Past Week

ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.

Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2021 Results - Earnings Call Transcript

ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021.

Stereotaxis Reports 2021 Second Quarter Financial Results

Stereotaxis Inc. (STXS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors.

News for Stereotaxis Inc Stock (STXS)